{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-22-000017","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.034980+00:00","generated_at":"2026-06-24T00:48:17.204747+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeuroPace Q2 revenue $10.2M (-19% YoY); net loss $12.7M; signs exclusive DIXI Medical SEEG distribution deal","bullets":["Q2 total revenue $10.2M vs $12.6M YoY; initial implant revenue $8.0M, replacement $2.2M.","Net loss $12.7M vs $8.5M YoY; operating expenses $18.4M up from $14.0M.","FY 2022 guidance: total revenue $43-45M, initial implant $34-36M; DIXI Medical revenue ~$1.5M in Q4.","Signed exclusive 3-year U.S. distribution deal for DIXI Medical SEEG electrodes; total payments of $4.5M.","Cash and equivalents $92.4M, down from $103.2M at March 31; long-term borrowings $51.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-22-000017","json":"https://secwatch.observer/filing/0001528287-22-000017.json","markdown":"https://secwatch.observer/filing/0001528287-22-000017.md","text":"https://secwatch.observer/filing/0001528287-22-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828722000017/0001528287-22-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828722000017/npce-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:48:17.204747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}